menu

NEWS

Platomics Inks Deals With Sophia Genetics, Agilent for Automated IVDR Compliance Documentation

Jan 09, 2025 | genomeweb NEW YORK – Regulatory compliance software provider Platomics said Thursday that it has launched a pilot program with Agilent Technologies to offer customers laboratory documentation capabilities for next-generation sequencing tests developed under the European Union’s In Vitro Diagnostic Regulation (IVDR).  Separately, the Vienna-based firm said Wednesday that it has inked a partnership with Sophia Genetics to streamline the compliance documentation process for EU clinical laboratories developing NGS tests using Sophia’s products. Financial details for the two deals were not disclosed.  Through the collaboration, Agilent customers developing NGS tests can leverage Platomics’ PlatoX platform to generate documentation required...

READ MORE
NeuroKaire Closes $10M Funding Round 

Kearny, NJ. — Dec. 17, 2024 — NeuroKaire, a pioneering biotechnology company specializing in precision medicine in psychiatry and neurology, has successfully secured $10 million in funding to advance development of its clinical test which helps identify drug efficacy for depression patients. The funding will help the company scale operations and further expand pharmaceutical partnerships. GreyBird Ventures led the round and the company’s other investors include Meron Capital and Jumpspeed Ventures, among others.  Based on a simple blood draw, NeuroKaire can provide a new view into brain function, including drug response insights that are based on the combined neurobiology and clinical...

READ MORE
NeuroKaire Receives Clinical Laboratory Improvement Amendments Certification 

Comprehensive pharmacogenetic assay focused on psychiatry and neurology advances precision medicine for the brain. November 20, 2024 // PR Newswire NeuroKaire, a pioneering biotechnology company specializing in precision medicine in psychiatry and neurology, announced today that its Kearny, NJ-based laboratory has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.   NeuroKaire’s new CLIA laboratory’s first offering is a pharmacogenetic assay focused on psychiatric and neurological drugs. Pharmacogenetics is the study of the interaction between genetic variations and drug response. The comprehensive test analyzes 95 variants...

READ MORE
GEHA MENTAL HEALTH CENTER AND GENETIKA+ PARTNER ON NOVEL SOLUTIONS DRIVING PRECISION MEDICINE IN DEPRESSION

Geha Mental Health Center of Clalit Health Services and Genetika+ form a partnership to further develop and validate NeuroKaire for depression – a precision medicine tool combining stem-cell technology and AI for optimizing antidepressant choice TEL AVIV, March 11, 2024 The Research Authority of Geha Mental Health Center, Clalit Health Services, and Genetika+, a pioneer in precision medicine in the fields of psychiatry and neurology, are partnering to advance the development of tools to personalize depression treatment using stem-cell technology, Artificial Intelligence (AI) and advanced analytics. The collaboration between Genetika+ and Geha Mental Health Center is focused on the use of advanced...

READ MORE
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer’s Disease

Apr 22, 2024, 08:30 ET CAMBRIDGE, Mass., April 22, 2024 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer’s Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense’s currently ongoing Phase 2 AD clinical trial, leverages Genetika+’s state-of-the-art technology that derives frontal cortex neurons from individual patients’ blood to quantify drug-induced neuronal plasticity in vitro. The Genetika+ technology serves as a human AD disease model and will be used to correlate clinical response with cellular effects, for mechanistic drug insights and...

READ MORE
Hummingbird Diagnostics Announces Publication Evaluating miR-Blood’s Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

miR-Blood is capable of revealing highly cell-type specific patterns of small RNA expression March 6, 2024 08:00 AM Eastern Daylight Time HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in using blood-based small RNAs for early disease detection and characterization, today announced a publication in Scientific Data, a peer-reviewed, open-access journal launched by Nature. The study evaluated miR-Blood, Hummingbird Diagnostics’ small RNA expression dataset for eleven major components of human peripheral blood. A highly comprehensive blood cell type expression atlas for small RNAs, miR-Blood is capable of revealing highly cell-type specific patterns of small RNA expression, enabling a deeper understanding of blood and immune...

READ MORE
1 2 3 10
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER